April 25, 2018 / 12:06 PM / in 6 months

GSK rules out entering Shire takeover battle

LONDON (Reuters) - GlaxoSmithKline’s (GSK.L) chief executive said on Wednesday she had no interest in acquiring Shire (SHP.L), the London-listed rare diseases specialist that Takeda Pharmaceutical (4502.T) hopes to buy for some $64 billion.

The GlaxoSmithKline (GSK) logo is seen on top of GSK Asia House in Singapore, March 21, 2018. Picture taken March 21, 2018. REUTERS/Loriene Perera

Emma Walmsley, speaking to reporters after first-quarter results, said the British drugmaker’s focus was on deals to acquire early-stage experimental drugs that would help rebuild the company’s pharmaceuticals pipeline.

Reporting by Ben Hirschler; editing by Jason Neely

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below